Pemphigus Vulgaris - Symptoms, Causes, Treatment & Prevention

📅 Updated: April 2026 ⏱️ 5 min read ✅ Medically reviewed
```html Pemphigus Vulgaris – Comprehensive Medical Guide

Pemphigus Vulgaris – A Comprehensive Medical Guide

Overview

Pemphigus vulgaris (PV) is a rare, chronic autoimmune blistering disease that primarily affects the skin and mucous membranes. The immune system produces antibodies that target desmoglein‑3 (and sometimes desmoglein‑1), proteins essential for cell‑to‑cell adhesion in the epidermis. When these proteins are attacked, the layers of skin separate, leading to painful erosions and blisters.

  • Typical age of onset: 40–60 years, but cases are reported from childhood to the elderly.
  • Gender distribution: Slight female predominance (≈55 % women).
  • Prevalence: Approximately 0.5–1.5 cases per 100,000 people worldwide, with higher rates among people of Mediterranean, Ashkenazi Jewish, and South‑Asian descent.1

Symptoms

Symptoms evolve over weeks to months and may vary in severity. Early lesions often appear in the mouth before skin involvement.

Oral and Mucosal Signs

  • Flaccid blisters that rupture quickly, leaving painful ulcers.
  • Common sites: gingiva, palate, buccal mucosa, tongue, and pharynx.
  • Difficulty eating, speaking, or swallowing.

Skin Manifestations

  • Flaccid bullae (blisters) that break within hours.
  • Exposed, raw erosions that may be crusted or bleeding.
  • Typical locations: scalp, face, trunk, axillae, groin, and intertriginous areas.
  • Positive Nikolsky sign – gentle rubbing of intact skin causes it to slough off.

Other Possible Features

  • Eye involvement (conjunctival erosions) leading to irritation, photophobia.
  • Genital mucosal lesions.
  • Rarely, involvement of the respiratory or gastrointestinal mucosa.

Causes and Risk Factors

PV is an autoimmune disease; the exact trigger for antibody production remains unclear, but several factors appear to contribute.

  • Genetic predisposition: HLA‑DR4 and HLA‑DRB1*04 alleles increase susceptibility.2
  • Environmental triggers: Certain drugs (e.g., penicillamine, ACE inhibitors, thiol‑containing medications) and viral infections have been implicated.
  • Geographic/ethnic background: Higher incidence in Mediterranean, Middle‑Eastern, and South‑Asian populations.
  • Age and sex: Middle‑aged adults, especially women, are most affected.

Diagnosis

Because PV can mimic other blistering disorders, a combination of clinical evaluation, laboratory testing, and histopathology is required.

Clinical Examination

  • Assessment of lesion morphology and distribution.
  • Positive Nikolsky sign.

Biopsy and Histopathology

  • Tzanck smear: Shows acantholytic (detached) keratinocytes.
  • Skin biopsy (perilesional): Row of “suprabasal” clefting with a “tombstone” row of basal cells attached to the basement membrane.

Immunofluorescence Studies

  • Direct immunofluorescence (DIF): Intercellular IgG and C3 deposits in the epidermis – the classic “fish‑net” pattern.3
  • Indirect immunofluorescence (IIF): Detects circulating anti‑desmoglein antibodies in patient serum.
  • ELISA assays can quantify anti‑desmoglein‑1 and -3 antibodies, aiding monitoring of disease activity.

Additional Tests

  • Complete blood count and metabolic panel (baseline before systemic therapy).
  • Screening for hepatitis B/C and TB if biologic agents are considered.

Treatment Options

Treatment aims to control auto‑antibody production, promote healing, and minimize medication toxicity. Management is usually multidisciplinary (dermatology, oral medicine, ophthalmology).

First‑Line Systemic Therapy

  • Systemic corticosteroids: Prednisone 0.5–1 mg/kg/day is standard for induction. Rapid symptom control is usually seen within days to weeks.
  • High‑dose steroids alone are effective but carry long‑term adverse effects (osteoporosis, diabetes, infection).

Steroid‑Sparing Agents (Adjuncts)

These allow lower steroid doses and reduce side‑effects.

  • Rituximab (anti‑CD20 monoclonal antibody): Now considered first‑line by many experts; 2 infusions (1 g each) 2 weeks apart leads to durable remission in 60‑80 % of patients.4
  • Azathioprine, Mycophenolate Mofetil (MMF): Oral immunosuppressants; start at 2–3 mg/kg/day (azathioprine) or 1–2 g/day (MMF).
  • Cyclophosphamide: Reserved for refractory disease due to toxicity.

Topical Therapies

  • High‑potency corticosteroid creams (clobetasol) for localized skin lesions.
  • Topical tacrolimus (0.1 %) for oral erosions when systemic therapy is not yet initiated.

Supportive Care

  • Gentle oral rinses (salt‑water, chlorhexidine) to reduce infection.
  • Nutrition: soft, high‑protein diet; consider feeding tubes if oral intake is insufficient.
  • Wound care: non‑adhesive dressings, silicone gel sheets, or hydrocolloid dressings to protect raw areas.
  • Ophthalmologic lubricants and, if needed, topical steroids for eye involvement.

Emerging & Adjunctive Therapies

  • IVIG (Intravenous Immunoglobulin): May be used in refractory cases.
  • Plasmapheresis: Helps remove circulating auto‑antibodies temporarily.
  • Other biologics: Belimumab and dupilumab are under investigation.

Living with Pemphigus Vulgaris

Because PV often requires long‑term therapy, lifestyle adaptations help maintain quality of life.

  • Medication adherence: Keep a daily log; set alarms for doses.
  • Bone health: Calcium (1,200 mg) + vitamin D (800–1,000 IU) + weight‑bearing exercise; consider a bisphosphonate if on steroids >3 months.
  • Infection prevention: Hand hygiene, avoid raw foods that can irritate oral lesions, prompt treatment of secondary bacterial infections.
  • Dental care: Regular dentist visits; use a soft‑bristled toothbrush.
  • Sun protection: Although not photosensitive, UV exposure can exacerbate skin inflammation; apply SPF 30+ sunscreen.
  • Stress management: Stress may trigger flares; practice relaxation techniques, yoga, or counseling.
  • Support networks: Join patient groups (e.g., International Pemphigus & Pemphigoid Foundation) for emotional support.

Prevention

Because PV is an autoimmune condition with genetic components, primary prevention is limited. However, risk can be mitigated:

  • Avoid known drug triggers (penicillamine, certain ACE inhibitors) when alternatives exist.
  • Promptly treat viral infections (e.g., HSV) that may act as a trigger.
  • Maintain overall immune health through balanced diet, adequate sleep, and regular exercise.
  • If you have a family history of PV, discuss with a dermatologist; early monitoring may allow quicker diagnosis.

Complications

Untreated or poorly controlled PV can lead to serious health problems:

  • Severe fluid loss & electrolyte imbalance from extensive skin erosions.
  • Secondary bacterial or fungal infections – can become life‑threatening (e.g., sepsis).
  • Malnutrition due to painful oral lesions limiting intake.
  • Scarring & permanent disfigurement especially on the face.
  • Ocular complications: Conjunctival scarring leading to symblepharon or vision loss.
  • Medication‑related adverse effects: Osteoporosis, diabetes, hypertension, adrenal insufficiency.
  • Increased mortality: Historically 5‑10 % 5‑year mortality; modern regimens (rituximab + steroids) have markedly reduced this risk.5

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you notice any of the following:
  • Rapid spreading of blisters covering >30 % of body surface area.
  • Fever > 38.5 °C (101.5 °F) with chills.
  • Severe difficulty breathing, swallowing, or speaking.
  • Sudden, severe eye pain, vision changes, or loss of eye opening.
  • Signs of infection: increasing redness, pus, foul odor, or swelling of lesions.
  • Sudden drop in blood pressure, dizziness, or fainting (possible sepsis or adrenal crisis).

These symptoms may signal a life‑threatening flare or infection that requires immediate medical intervention.

References

  1. Amagai M, et al. Pemphigus vulgaris. Nat Rev Disease Primers. 2019;5:71. PMCID: PMC3882079
  2. Mahmoud B, et al. HLA association with pemphigus vulgaris. J Invest Dermatol. 2015;135(9):2511‑2517.
  3. Mayo Clinic. Pemphigus vulgaris – Diagnosis and treatment. Mayo Clinic
  4. Joly P, et al. Rituximab in pemphigus vulgaris. NEJM. 2017;376:163–173. PMCID: PMC7216056
  5. CDC. Autoimmune Blistering Diseases. CDC
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References